Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ivabradine

- PMLiVE

Amgen starts shipping Corlaner in US

Firm also reports healthy financial growth in the first quarter

- PMLiVE

FDA clears Amgen’s Corlaner for heart failure

It is the firm’s first cardiovascular product to gain approval

- PMLiVE

Amgen gets EU nod for wider use of Vectibix

US biotech’s cancer therapy can now be used in a first-line setting

- PMLiVE

Amgen gets quick US review for Kyprolis

To be considered as a second-line therapy for multiple myeloma

- PMLiVE

Icelandic genome study yields new disease genes

Nature Medicine study focuses on the probability of developing Alzheimer’s

- PMLiVE

FDA panel backs GSK’s asthma drug Breo for adults only

Already approved to treat COPD in the US

- PMLiVE

FDA clears first therapy for rare childhood cancer

United Therapeutics’ Unituxin approved for neuroblastoma

- PMLiVE

FDA approves first biosimilar

Novartis’ Sandoz unit gains new licence for Neupogen copycat

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Amgen hoping to topple Takeda’s $2bn a year drug

- PMLiVE

Actavis gets FDA nod for new antibiotic

Avycaz is the fifth antibiotic to gain US approval in recent months

- PMLiVE

Novartis gets OK for panobinostat in myeloma

First HDAC to receive positive FDA review

- PMLiVE

Novartis’ heart failure drug could get FDA nod in summer

Some predicting sales of $5bn within four years for LCZ696

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links